Tachosil® in hepatobiliary surgery - our experience
TachoSil® is a product used in surgical branches of medicine as a supportive therapy. Specifically, this product is used for local support of haemostasis and tissue sealing during surgical treatment where satisfactory results have not been achieved by conventional techniques. We observed the duration of intraoperative hemostasis, compared it with already available results showing the duration of haemostasis in other cases and clearly demonstrated the benefits of TachoSil®. In a sample of ten patients with intraoperative use of TachoSil®, the mean value of haemostasis was 4.2 min (3.2 min-7 min). A leakage of bile into the abdominal drain was observed in only one patient after the administration of TachoSil®. In hepatobiliary surgery, cost/benefit ratio is undoubtedly in favour of TachoSil®. Our results correlate well with those of our colleagues from around the world.
TachoSilR product monograph, Denmark, September 2011.
Škegro M, Romić B, Gojević A, Baotić T, Deban O, Petrović I: Kirurško liječenje jetrenih metastaza; 7. kongres Hrvatskog društva za digestivu kirurgiju - usmeno priopćenje.
Sierra DH. Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications. J Biomater Appl 1993;7:309-52.
Bloom AL. Physiology of blood coagulation. Haemostasis 1990;20:14-29.
Erdogan D, de Graaf W, van Gulik TM. Adhesive strength of fibrinogencoated collagen patch or liquid fivrin sealant in an experimental liver resection model in pigs. Eur Surg Res 2008;41:298-302.
Nycomed Clinical Trial Report. Trial ID – TC-014-IN. An open, randomised, prospective, multicentre, parallel-group phase III trial to compare efficacy and safety of TachoCombR S and argon beamer in patients undergoing liver resection. 2002.
Nycomed Clinical Trial Report. Trial ID – TC-016-IN. An open, randomised, prospective, multicentre, parallel-group trial to compare efficacy and safety of TachoCombR S versus argon beam coagulator treatment in subjects undergoing liver resection (II). 2003.
Broelsch CE, Fruhaus NR, de Hemptinne B, et al. TachoSilR as haemostatic treatment in hepatic surgery. HPB 2005;7:28.
Frilling A, Stavrou G, Mischinger HJ, et al. Effectiveness of a new carrierbound fibrin sealant versus argon beamer as hemostatic agent during liver resection: a randomized prospective trial. Langenbeck’s Arch Surg 2005;390:114-20.
Briceno J, Naranjo A, Ciria R, et al. A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection Arch Surg 2010;145:482-8.
Toti L, Attia M, Manzia TM, et al. Reduction in bile leaks following adult split liver transplant using a fibrin-collagen sponge: A pilot study. Dig Liver Dis. 2010;42:205-9.
Pozzo G, Amerio G, Bona R, et al. A new method of jejunal reconstruction after pancreaticoduodenectomy. Hepatogastroenterology 2010;57:1305-8.
Chirletti P, Caronna R, Fanello G, et al. Pancreaticojejunostomy with application of fibrinogen/thrombin-coated collagen patch (TachoSilR) in Roux-en-Y reconstruction after pancreaticoduodenectomy. J Gastrointest Surg 2009;13:1396-8.
Fischer L, Seiler CM, Broelsch CE, et al. Hemostatic efficacy of TachoSilR in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery 2011;149:48-55.
Lang G, Csekeo A, Stamatis G, et al. Efficacy and safety of topical application of human fibrinogen/thrombin-coated collagen patch (TachoCombR) for treatment of air leakage after standard lobectomy. Eur J Cardiothorac Surg 2004;25:160-6.
Nycomed Clinical Trial Report. Trial ID – TC-013-IN. An open, randomised, prospective, multicentre, parallel-group phase III trial to compare efficacy and safety of TachoCombR S versus standard surgical treatment in patients undergoing lung lobectomy for lung cancer and requiring treatment for air leakage after primary stapling. 2004.
Eloy R. Comparative hemostatic wound sealing effect and resistance of absorbable TachoCombR H and TachoCombR S – Experimental study in the pig model of acute pancreatitis. Study No. 73E801. Nycomed Research Report No. 5127. 1998.
Rolle U, Schneider A, Weib J, et al. Histological findings of TachoCombR applied on serosal defects in a rabbit model. 5th World Congress on Trauma, Shock, Inflammation and Sepsis, 26 February - 4 March 2000, Munich, Germany.
Schelling G, Block T, Blanke E, et al. The effectiveness of a fibrinogenthrombin-collagen-based hemostatic agent in an experimental arterial bleeding model. Ann Surg 1987;205:432-5.
Schelling G, Block T, Gokel M, et al. Application of a fibrinogenthrombincollagen-based hemostyptic agent in experimental injuries of liver and spleen. J Trauma 1988;28:472-5.
Martis G, Miko I, Szendroi T, et al. Results with collagen fleece coated with fibrin glue (TachoCombR). A macroscopical and histological experimental study. Acta Chir Hung 1997;36:221-2.
Copyright (c) 2012 Acta Chirurgica Croatica
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby authorize the Acta Chirurgica Croatica (ACC) to publish their work.
The authors are aware that although ACC is Open Access journal, the copyright of all material published is vested in ACC. Open access articles are freely available to read, download, and share from the time of publication under the terms of the Creative Commons License Attribution ‐ NonCommerical No Derivative (CC BY‐NC‐ND) license. This license does not permit reuse for any commercial purposes nor does it cover the reuse or modification of individual elements of the work (such as figures, tables, etc.) in the creation of derivative works without specific permission of ACC and appropriate acknowledgment of its source. The authors permit ACC to allow third parties to copy any part of the work without asking for permission, provided that the reference to the source is given and that this is not done for commercial purposes. Except for copyright, other proprietary rights related to the work (e.g., patent or other rights to any process or procedure) shall be retained by the author. To reproduce any text, figures, tables, or illustrations from this work in future works of their own, the author must obtain written permission from ACC.
Each of the author(s) hereby also grants permission to ACC to use such author’s name and likeness in connection with any past, present or future promotional activity by ACC, including, but not limited to, promotions for upcoming issues or publications, circulation solicitations, advertising or other publications in connection with ACC. Also, each of the author(s) hereby grants permission to ACC to use the manuscript in editorial research related to the improvement of editorial conduct, decision making, and issues related to peer review.
Each of the author(s) hereby releases and shall indemnify and hold harmless ACC and its successors, assigns, licensees, officers, directors, employees, and their respective heirs and representatives from and against any and all liabilities, losses, damages and expenses arising out of any claims of any kind that may be asserted against any of them based in whole or in part on any breach of the author(s)’ representations or warranties herein or in the work or anything contained in the work, including but not limited to any claims for copyright infringement or violation of any rights of privacy or publicity.